Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions

Acta Cytologica

Volumn 54, Issue 3, 2010, Pages 277-282

  Kim, Jo Heon ^a   Choi, Yoo Duk ^a   Lee, Ji Shin ^a   Lee, Jae Hyuk ^a   Nam, Jong Hee ^a   Choi, Chan ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Adenocarcinoma; CDX 2; Immunocytochemistry; Serous effusion; Thyroid transcription factor 1

Indexed keywords

ANTIBODY; CALRETININ; MOC 31 ANTIBODY; MONOCLONAL ANTIBODY D2-40; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT ADENOCARCINOMA; BILE DUCT CARCINOMA; BREAST ADENOCARCINOMA; COLON ADENOCARCINOMA; DIAGNOSTIC VALUE; EFFUSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG ADENOCARCINOMA; MEDICAL RECORD REVIEW; METASTASIS; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; STAINING; STOMACH ADENOCARCINOMA;

EID: 77953204817     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000325035     Document Type: Article

References (23)

1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005
2. Pavlidis N, Fizazi K: Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009;69:271-278
3. Koss LG (editor): Koss' Diagnostic Cytology and Its Histopathological Bases. Fifth edition. Philadelphia, Lippincott Williams & Wilkins, 2006
4. Fang F, Yang L, Su XL, He Q, Liu DG, Lin FR, Ma ZZ: Determining the primary site of metastatic adenocarcinoma in serous fluid: A cytological study. Zhonghua Bing Li Xue Za Zhi 2005;34:641-645
5. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-3772
6. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007;131:1561-1567 (Pubitemid 47606722)
7. Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A: Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med 2007;131:1686-1690 (Pubitemid 350077466)
8. Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y: Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007;15:407-414
9. Werling RW, Yaziji H, Bacchi CE, Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-310
10. Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C: CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 2003;27:141-149
11. Jang KY, Kang MJ, Lee DG, Chung MJ: Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001;23:400-404
12. Ng WK, Chow JC, Ng PK: Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 2002;96:43-48
13. Afify AM, al-Khafaji BM: Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 2002;46:675-678
14. Gomez-Fernandez C, Jorda M, Delgado PI, Ganjei-Azar P: Thyroid transcription factor 1: A marker for lung adenocarcinoma in body cavity fluids. Cancer 2002;96:289-293
15. Pomjanski N, Grote HJ, Doganay P, Schmiemann V, Buckstegge B, Böcking A: Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol 2005;33:309-315
16. Fetsch PA, Simsir A, Brosky K, Abati A: Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61-66
17. Kim JH, Kim GE, Choi YD, Lee JS, Lee JH, Nam JH, Choi C: Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol 2009;37:258-261
18. Bedrossian CW: Special stains, the old and the new: The impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 1998;18:141-149
19. Prok AL, Prayson RA: Thyroid transcription factor-1 staining is useful in identifying brain metastases of pulmonary origin. Ann Diagn Pathol 2006;10:67-71
20. Tan D, Li Q, Deeb G, Ramnath N, Slocum HK, Brooks J, Cheney R, Wiseman S, Anderson T, Loewen G: Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604
21. Li MK, Folpe AL: CDX-2, a new marker for adenocarcinoma of gastrointestinal origin. Adv Anat Pathol 2004;11:101-105
22. Saad RS, Essig DL, Silverman JF, Liu Y: Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinoma in fine-needle aspiration cytology using cell blocks. Cancer 2004;102:168-173
23. Levine PH, Joutovsky A, Cangiarella J, Yee H, Simsir A: CDX-2 expression in pulmonary fine-needle aspiration specimens: A useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma. Diagn Cytopathol 2006;34:191-195